Zydus says Delhi HC order on cancer drug IkraTM is not material

Regulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹1133.80

prior close

₹1145.10

announcement price

After-mkt

timing

Nifty 100market+0.2%+2.2% vs market

Pharmaceuticals peers, median of 165sector+0.0%+2.4% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty 100 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.8

15m

-0.6

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.2+2.2+0.0+2.4

Next day

+1.5+0.1+1.4+0.0+1.5

+0.9+1.0-0.1-1.1+2.0

+1.3+0.8+0.5-0.5+1.8

+1.1+0.7+0.4-0.4+1.4

-0.8-0.1-0.7-1.7+0.9

-2.1-1.0-1.1-2.6+0.5

15d

-1.1+2.6-3.7-1.2+0.1

-0.2+1.5-1.7-0.5+0.3

-3.1-3.6+0.5-0.3-2.8

+0.6-4.4+5.0-2.3+2.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

BSE asked Zydus Lifesciences to clarify a Delhi High Court order that temporarily restricts the company from supplying its cancer drug IkraTM. Zydus responded that this event is not material under SEBI listing rules and its own materiality policy. The company said there was no material movement in its share price on July 14, 2026, and believes the order will not have a material impact on its business or operations.

Likely market impact

Company downplays court order restricting cancer drug supply; maintains no material impact on business or stock trading.